can you take tirzepatide with metformin Mixing Mounjaro and metformin: Safety, side effects, and interactions Could GLP-1 Weight Loss Drugs

Spinal melanotic schwannoma: a tumour with poor prognosis

Slippery Elm & Dandelion to support digestive wellness and gut function

Consequently, companies such as Novo Nordisk and Eli Lilly are investing heavily in next-generation formulations, including oral small-molecule GLP-1 receptor agonists such as orforglipron, which aim to expand patient accessibility and therapeutic scope The demand for GLP-1 drugs that address a wider array of metabolic conditions is growing rapidly across global markets, as patients and healthcare providers increasingly seek holistic and effective long-term treatment options for obesity and its comorbidities GLP-1 Receptor Agonists Obesity Drugs Market Dynamics Driver Surging Demand Due to Rising Obesity Prevalence and Enhanced Clinical Outcomes The global surge in obesity rates and associated comorbidities such as type 2 diabetes and cardiovascular diseases is significantly driving demand for GLP-1 receptor agonist drugs as effective medical weight loss therapies For instance, in May 2024, Novo Nordisk announced a USD 4.1 billion expansion in its U.S

Dietary fiber in gastrointestinal health and disease

doi: 10.1016/S0025-7125(16)36314-3 175